{
  "denotations": [
    {
      "id": "T1",
      "obj": "Disease",
      "span": {
        "begin": 66,
        "end": 69
      }
    },
    {
      "id": "T2",
      "obj": "Chemical",
      "span": {
        "begin": 84,
        "end": 94
      }
    },
    {
      "id": "T3",
      "obj": "Chemical",
      "span": {
        "begin": 116,
        "end": 128
      }
    },
    {
      "id": "T4",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 168,
        "end": 192
      }
    },
    {
      "id": "T5",
      "obj": "Chemical",
      "span": {
        "begin": 155,
        "end": 165
      }
    },
    {
      "id": "T6",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 195,
        "end": 198
      }
    },
    {
      "id": "T7",
      "obj": "Disease",
      "span": {
        "begin": 262,
        "end": 265
      }
    },
    {
      "id": "T8",
      "obj": "Chemical",
      "span": {
        "begin": 97,
        "end": 111
      }
    },
    {
      "id": "T10",
      "obj": "Chemical",
      "span": {
        "begin": 168,
        "end": 210
      }
    },
    {
      "id": "T9",
      "obj": "Chemical",
      "span": {
        "begin": 131,
        "end": 148
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "26103436_16",
  "text": "At the time of relapse , agents directed at activated pathways in MCL cells such as bortezomib ( NFkB inhibitor ) , lenalidamide ( anti-angiogenesis ) and Ibruitinib ( Bruton's Tyrosine Kinase [ BTK ] inhibitor ) have demonstrated excellent clinical activity in MCL patients ."
}
